Q1 2020 SS&C Intralinks Deal Flow Predictor: Opportunity Ahead for Global M&A
Can 2020 build on H2 2019’s recovery?
2 December 2019
The Q1 2020 SS&C Intralinks Deal Flow Predictor is out – and the forecast is promising for the continued global mergers and acquisitions (M&A) recovery that began in the second half of 2019.
In Q1 2020, deal announcements are anticipated to keep rising – with a +6 percent increase (range +11 to +1 percent.)
This unique insight comes thanks to analysis by Refinitiv1 and Intralinks, using predictive models to forecast the volume of new deal M&A announcements worldwide over the next six months.
A breakout sector kicks off Q1
After a decline in M&A growth for H1 2019, the H2 recovery was pushed by the Energy & Power and Materials sectors. While both sectors are still providing some power, H1 2020 is expected to be fueled by TMT (Technology, Media & Telecoms) and Healthcare in North America.
Energy and Power still play a strong role in LATAM and EMEA, however.
2019’s strongest regions maintain growth
Regionally, APAC and North America are forecast to bring about a 7 percent increase in M&A growth, with both touting a possible high of more than 10 percent (+12 for APAC and +15 for NA). While EMEA projects a +5 increase, LATAM, as in H2 2019, lags behind with a predicted decrease of -4 on the horizon.
Find out more in the Q1 2020 SS&C Intralinks Deal Flow Predictor.
Independently verified as a highly accurate six-month forecast of merger and acquisition (M&A) activity, the SS&C Intralinks Deal Flow Predictor is compiled by tracking early-stage M&A transactions globally that are in preparation or have begun due diligence.
Along with our forecast of M&A activity for the next six months, the latest issue of the SS&C Intralinks Deal Flow Predictor includes:
Spotlight feature: Are national security concerns affecting infrastructure M&A?
An interview with Ken Schultz, M.D., CEO & Chairman of Los Angeles-based biopharmaceutical oncology company Trethera. He reflects on business development war stories from the biopharma front line, offering an exclusive insider’s view of transactions he’s led during his two decades of dealmaking.
1Thomson Reuters’ data on the number of announced deals for the past four quarters has been adjusted by SS&C Intralinks for expected subsequent changes in reported announced deal volumes in Refinitiv’s database.